Juçara Supplementatios After Muscle DamageNCT07584460

Juçara (Euterpe Edulis Martius) Supplementation Effect in Muscle Protection, Performance and Soreness in Lower Limbs After Exercise-Induced Muscle Damage

A study testing Juçara in people with Juçara Supplementatios After Muscle Damage, run by Universidade Federal de Santa Maria at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 40 years, men only
Conditions the study is for: Juçara Supplementatios After Muscle Damage
What is being tested?: Juçara
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 24 participants
Where: 1 siteBrazil
Study dates: 3 Jun 2024to 2 Dec 2024
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 40 years
Men only
No healthy volunteers
Adult

Who may be able to join

Males
Aged 18-40 years
Physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire
No history at lower-limb within the previous six months
No medical restrictions for maximal exercise testing
No allergy to red fruits

Show all 10Show fewer

No physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol
No history of lower-limb surgery
No use nutritional supplements within 30 days prior to study initiation
Abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.

Who cannot join

Individuals younger than 18 or older than 40 years
Not physically active, defined as performing fewer than three exercise sessions per week according to IPAQ questionnaire
Presence of history at lower-limb injury within the previous six months
Presence of medical restrictions for maximal exercise testing
Known allergy to red fruits
Presence of physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol

Show all 9Show fewer

History of lower-limb surgery
Use of nutritional supplements within 30 days prior to study initiation
Inability to abstain from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol

Trial locations and contacts

1 site in 1 country.

Brazil1 site

Centro de Educação Física e Desportos
Santa Maria, Rio Grande do Sul, 97105900

Other trials in Brazil

About this study

Official title: Juçara (Euterpe Edulis Martius) Supplementation Effect in Muscle Protection, Performance and Soreness in Lower Limbs After Exercise-Induced Muscle Damage: A Six-Week Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

The purpose of this study is to find out if taking a natural supplement made from the Juçara fruit (a Brazilian berry rich in antioxidants called anthocyanins) can help the body recover faster after damage caused by exercise. Researchers want to see if Juçara can reduce muscle soreness and help muscles regain their strength and quality more quickly compared to a placebo (a "dummy" pill with no active ingredients).

What happens during the study? The study included 24 healthy, active men. It was a "crossover" study, meaning every participant tried both the Juçara supplement and the placebo at different times.

Supplement Phase: Participants took 12 capsules a day for 7 days.

Muscle Damage Test: To cause temporary muscle damage, participants performed a specific jumping protocol (100 maximal jumps).

Recovery Monitoring: Researchers tracked the participants for 72 hours after the jumps to measure:

How high they could jump (strength/performance).

Muscle soreness (using a pain scale).

Muscle "quality" and stiffness (using ultrasound imaging).

Wait Period: After the first phase, participants waited 14 days (washout) before switching to the other supplement to repeat the process.

Conditions: Juçara Supplementatios After Muscle Damage
Being tested: Juçara, Placebo group
Keywords: Juçara, Muscle damage, Performance, Echointensity, Jump

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

JuçaraDietary supplement
Total of 11 separate occasions under the Juçara condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (Juçara) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.
Placebo groupDietary supplement
Total of 11 separate occasions under the placebo condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (placebo) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.

Study groups in NCT07584460
Study group	Role	What they receive
Juçara group	Experimental	The sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol. Receives: Dietary Supplement: Juçara
Placebo Group	Placebo comparator	The sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol. Receives: Dietary Supplement: Placebo group

What is being measured

The primary outcome is the main question the study is designed to answer.

Countermovement Jump Height
Countermovement Jump (CMJ) hieght will be measured to assess using two force plates (AMTI OR6-6-2000; 1000 Hz). Measurements will be obtained at Baseline (Pre), and at 24, 48, and 72 hours following the exercise induced muscle damage (EIMD) protocol. Data will be expressed in centimeters (cm). Jump height will be calculated using take-off velocity and projectile motion principles.
Measured: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Contermovement jump power
Countermovement Jump (CMJ) power will be evaluated using two force plates (AMTI OR6-6-2000; 1000 Hz). Peak power will be calculated based on the jump flight time or force-time curve. Assessments will be performed at Baseline (Pre), 24h, 48h, and 72h post exercise induced muscle damage. Data will be expressed in Watts (W). Power during the concentric phase (i.e., the propulsive phase; interval between the onset of propulsion and take-off) will be calculated by multiplying force by velocity.
Measured: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and hamstrings Echointensity
Quadriceps and Hamstrings muscle echointensity will be assessed using ultrasonography to evaluate muscle damage. Images will be analyzed through gray-scale histogram analysis using ImageJ software. Assessments will be performed at Baseline (Pre-exercise), and at 24 hours, 48 hours, and 72 hours following the exercise-induced muscle damage (EIMD) protocol. Data will be expressed in arbitrary units (AU).
Measured: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings Cross-Sectional Area
Muscle Cross-Sectional Area from Quadriceps and Hamstrings will be assessed using an ultrasound with extended field of view mode at 50% of limb length. Quadriceps and Hamstrings Cros-Sectional areas will be expressed in cm².
Measured: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol
Vastus Lateralis and Biceps Femoris Long Head stiffness
Vastus Lateralis and Biceps Femoris Long Head muscle stiffness will be assessed using Shear Wave Elastography mode from an ultrasound. Muscle stiffness will be expressed in kilopascal (kPa).
Measured: From pre Exercise Muscle Damage Protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings muscle soreness
Muscle soreness of the quadriceps will be assessed using a Visual Analogue Scale (VAS). Measurements will be obtained at Baseline (Pre-exercise), Immediately Post-exercise, 24 hours, 48 hours, and 72 hours following the Exercise Induced Muscle Damage (EIMD) protocol. Data will be expressed on a scale from 0 (no soreness) to 30 centimeters (worst possible soreness).
Measured: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

3 Jun 20242 Dec 2024

First posted13 May 2026
Study start3 Jun 2024
Primary completion3 Oct 2024
Study completion2 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Juçara Supplementatios After Muscle DamageStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Model description: Crossover study with juçara and placebo supplementation with 14 days washout period.
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 24 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07584460
Sponsor's protocol ID: 6.753.984
Other IDs: UFSM
Status last verified: May 2026
First submitted: 30 Apr 2026
Last updated: 13 May 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Study at a glance

From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Juçara (Euterpe Edulis Martius) Supplementation Effect in Muscle Protection, Performance and Soreness in Lower Limbs After Exercise-Induced Muscle Damage: A Six-Week Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
ClinicalTrials.gov ID: NCT07584460
Acronym / sponsor ID: 6.753.984
Conditions: Juçara Supplementatios After Muscle Damage
Keywords: Juçara, Muscle damage, Performance, Echointensity, Jump
Study type: Interventional
Recruitment status: Completed
Enrolment: 24 participants (actual)
Lead sponsor: Universidade Federal de Santa MariaUniversity, hospital or other
Study start: 3 Jun 2024 (actual)
Primary completion: 3 Oct 2024 (actual)
Study completion: 2 Dec 2024 (actual)
First posted: 13 May 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

What happens during the study? The study included 24 healthy, active men. It was a "crossover" study, meaning every participant tried both the Juçara supplement and the placebo at different times.

Supplement Phase: Participants took 12 capsules a day for 7 days.

Muscle Damage Test: To cause temporary muscle damage, participants performed a specific jumping protocol (100 maximal jumps).

Recovery Monitoring: Researchers tracked the participants for 72 hours after the jumps to measure:

How high they could jump (strength/performance).

Muscle soreness (using a pain scale).

Muscle "quality" and stiffness (using ultrasound imaging).

Wait Period: After the first phase, participants waited 14 days (washout) before switching to the other supplement to repeat the process.

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: Crossover study with juçara and placebo supplementation with 14 days washout period.

Arm	Type	Receives
Juçara group	Experimental	Dietary Supplement: JuçaraThe sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.
Placebo Group	Placebo comparator	Dietary Supplement: Placebo groupThe sample consisted of 24 healthy, physically active men with any kind of experience in any physical exercise modality. Eligibility criteria were as follows: (1) male, aged 18-40 years; (2) physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire; (3) no history at lower-limb within the previous six months; (4) no medical restrictions for maximal exercise testing; (5) no allergy to red fruits; (6) no physical, cognitive and/or psychological limitations affecting the execution or understanding of the protocol; (7) no history of lower-limb surgery; (8) no use nutritional supplements within 30 days prior to study initiation; and (9) abstention from caffeine, cacao, yerba mate tea, and soft drinks during the study protocol.

Who may qualify

Ages: 18 to 40 years
Sex: Male only
Healthy volunteers: Not accepted
Age groups: Adult

Key inclusion criteria (10 listed)

Males
Aged 18-40 years
Physically active, defined as performing at least three exercise sessions per week according to IPAQ questionnaire
No history at lower-limb within the previous six months
No medical restrictions for maximal exercise testing

Key exclusion criteria (9 listed)

Individuals younger than 18 or older than 40 years
Not physically active, defined as performing fewer than three exercise sessions per week according to IPAQ questionnaire
Presence of history at lower-limb injury within the previous six months
Presence of medical restrictions for maximal exercise testing
Known allergy to red fruits

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
JuçaraTotal of 11 separate occasions under the Juçara condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (Juçara) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.	Dietary supplement	Juçara group
Placebo groupTotal of 11 separate occasions under the placebo condition. A familiarization session of CMJ and EIMD protocol (10 sets of CMJ repetitions with 1-minute rest between sets) was performed, followed by a 14-day washout period. During this visit, volunteers' descriptive data were assessed. On day 1 of this condition (72h pre EIMD), body mass was obtained, and participants received the supplementation (placebo) to be consumed for 7 days (one capsule every 12 h). On day 2, the CSA from QUAD and HAMS, elastography from vastus lateralis (VL) and biceps femoris long head (BFlh) of the dominant limb, and the CMJ performance were assessed. After that, participants performed the EIMD protocol. Follow-up assessments were conducted at 24 h (day 3), 48 h (day 4), and 72 h (day 5) post-EIMD, repeating the same measurements. A 14-day washout period separated the two interventions.	Dietary supplement	Placebo Group

Primary outcome

Countermovement Jump Height
Time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Countermovement Jump (CMJ) hieght will be measured to assess using two force plates (AMTI OR6-6-2000; 1000 Hz). Measurements will be obtained at Baseline (Pre), and at 24, 48, and 72 hours following the exercise induced muscle damage (EIMD) protocol. Data will be expressed in centimeters (cm). Jump height will be calculated using take-off velocity and projectile motion principles.
Contermovement jump power
Time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Countermovement Jump (CMJ) power will be evaluated using two force plates (AMTI OR6-6-2000; 1000 Hz). Peak power will be calculated based on the jump flight time or force-time curve. Assessments will be performed at Baseline (Pre), 24h, 48h, and 72h post exercise induced muscle damage. Data will be expressed in Watts (W). Power during the concentric phase (i.e., the propulsive phase; interval between the onset of propulsion and take-off) will be calculated by multiplying force by velocity.
Quadriceps and hamstrings Echointensity
Time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Quadriceps and Hamstrings muscle echointensity will be assessed using ultrasonography to evaluate muscle damage. Images will be analyzed through gray-scale histogram analysis using ImageJ software. Assessments will be performed at Baseline (Pre-exercise), and at 24 hours, 48 hours, and 72 hours following the exercise-induced muscle damage (EIMD) protocol. Data will be expressed in arbitrary units (AU).
Quadriceps and Hamstrings Cross-Sectional Area
Time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol
Muscle Cross-Sectional Area from Quadriceps and Hamstrings will be assessed using an ultrasound with extended field of view mode at 50% of limb length. Quadriceps and Hamstrings Cros-Sectional areas will be expressed in cm².
Vastus Lateralis and Biceps Femoris Long Head stiffness
Time frame: From pre Exercise Muscle Damage Protocol to Post-72h Exercise Induced Muscle Damage protocol.
Vastus Lateralis and Biceps Femoris Long Head muscle stiffness will be assessed using Shear Wave Elastography mode from an ultrasound. Muscle stiffness will be expressed in kilopascal (kPa).
Quadriceps and Hamstrings muscle soreness
Time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.
Muscle soreness of the quadriceps will be assessed using a Visual Analogue Scale (VAS). Measurements will be obtained at Baseline (Pre-exercise), Immediately Post-exercise, 24 hours, 48 hours, and 72 hours following the Exercise Induced Muscle Damage (EIMD) protocol. Data will be expressed on a scale from 0 (no soreness) to 30 centimeters (worst possible soreness).

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Juçara in people with Juçara Supplementatios After Muscle Damage, run by Universidade Federal de Santa Maria at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Countermovement Jump Height (time frame: From pre Exercise Induced Muscle Damage protocol to Post-72h Exercise Induced Muscle Damage protocol.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07584460.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.